Modeling and Simulation Project Embedment Lead - Data and AI Acceleration
About the job
- A Master's degree with 8–10 years of experience or a PhD with 5–8 years of experience in Statistics, Data Sciences, or a related quantitative discipline.
- Strong experience working in clinical trial design as a statistician or data scientist.
- Applied understanding of how modeling and simulation and artificial intelligence can augment clinical trial workflows, with an eye for high-impact use cases.
- Ability to bridge business and technical teams by translating end-user needs into developer-ready requirements.
- Experience in change management or process improvement within drug development.
- Strong communication, facilitation, and stakeholder engagement skills.
- Ability to design pragmatic, fit-for-purpose governance frameworks.
- Map current workflows and identify modeling and simulation and artificial intelligence automation and augmentation opportunities.
- Oversee embedment and adoption of modeling and simulation and artificial intelligence tools across the Therapeutic Areas.
- Work closely with solution developers to translate business problems into actionable requirements and ensure delivered tools meet end-user needs.
- Reimagine and define fit-for-purpose ways of working, processes, and templates in collaboration with cross-functional partners that evolve with modeling and simulation and artificial intelligence adoption.
- Train, onboard, and enable end-users on new modeling and simulation and artificial intelligence tools to drive adoption and effective use.
- Monitor adoption metrics and identify barriers; iterate on processes to reduce friction and feed insights back to inform prioritization of new use cases.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Flexible Work Hours
- Professional Development Budget
Growth & Insights and Company News
6 month growth
4%1 year growth
5%2 year growth
5%AbbVie (NYSE: ABBV) looks well placed to keep paying dividends through any interest rate cycle, according to a Motley Fool analysis. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Laboratories, which makes it a Dividend King. It generates more than enough free cash flow to cover its quarterly dividend of $1.73 per share. Of its $70.8 billion in debt, much is fixed-rate, so rate moves matter less. Skyrizi and Rinvoq brought in over $7.5 billion in the second quarter of 2026, above the $6.1 billion paid in dividends. About 90 programs are in clinical development. The dividend yield is 2.5%, lower than in the past because the share price has climbed. Pipeline setbacks remain a risk.
Altria beats AbbVie as a 10-year dividend holding, according to a TIKR analysis. Altria yields 6.2% against AbbVie's 2.6%, so $10,000 invested would pay about $7,484 over the decade from Altria, versus about $3,519 from AbbVie. AbbVie lowered its 2026 adjusted earnings per share guidance to $13.76 to $13.96, citing $1.25 billion of acquired research and milestone expense. Its payout ratio has climbed from 41% in fiscal 2022 to 65% in fiscal 2025, and net debt stands at 2.06 times EBITDA. Altria's payout ratio has stayed between 75% and 82% since fiscal 2021. It trades at 12.4 times forward earnings, against 18.0 for AbbVie. The main risk for Altria is that cigarette volumes fall faster than nicotine pouch sales can offset.
A Motley Fool comparison of AbbVie and Novo Nordisk concludes AbbVie is the better long-term buy in 2026, even though Novo looks cheaper. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, but net income was $4.2 billion. Novo Nordisk's revenue grew 6.4% to $46.3 billion, with net income of $15.3 billion. Novo trades at 11.7 times forward earnings against AbbVie's 20.2. Analysts expect Novo's 2026 sales to fall about 3% on pricing pressure and rivalry from Eli Lilly. AbbVie is forecast to grow net income to $14.6 billion on $67.2 billion in sales, helped by its $10.9 billion Apogee Therapeutics deal and its Skyrizi and Rinvoq drugs.
AbbVie shares have climbed to $281.12, up 9.33% in a month and 22.59% so far this year, after a run of clinical and regulatory news. Total shareholder return is 25.85% over one year. The news includes Phase 3 Crohn's disease results for SKYRIZI and RINVOQ, and FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer. AbbVie also released early obesity data for ABBV-295 and Phase 2 atopic dermatitis results for zumilokibart. Simply Wall St's most followed narrative puts fair value at $278.61, leaving the stock 1% overvalued. Its discounted cash flow model estimates $497.77, which would put the shares about 43.5% below fair value. Risks include tighter drug price pressure and faster than expected competition for Skyrizi and Rinvoq.
A comparison of AbbVie and Eli Lilly favours Eli Lilly for long-term investors, driven by its strong weight-loss and diabetes drug franchise. Lilly's 2025 revenue rose 44.7% to $65.2 billion, with net income of $20.6 billion. AbbVie's revenue grew 8.6% to $61.2 billion, with net income of $4.2 billion, as Skyrizi and Rinvoq replace ageing Humira sales. Lilly trades at a forward price-to-earnings ratio of 33.1x, against 19.8x for AbbVie. Lilly expects 2026 revenue of up to $85.2 billion, helped by Zepbound, Mounjaro and a new pill, Foundayo. AbbVie forecasts 2026 sales of $67.2 billion and net income of $14.6 billion. It is also acquiring Apogee Therapeutics.